Ovarian Cancer Regimens | Merrimack Pharmaceuticals (MM-121 + taxol/ErbB3) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Saturday, April 27, 2013

Ovarian Cancer Regimens | Merrimack Pharmaceuticals (MM-121 + taxol/ErbB3)



Merrimack Pharmaceuticals

"Through this approach we hope to generate additional knowledge on how ErbB3 signaling affects response to therapy, and then apply this understanding to identify patients that will most likely benefit from treatment regimens that include MM-121."

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.